Follow us on:

Poolbeg Pharma partner with Eurofins Genomics for AI data analysis (Interview)

Poolbeg Pharma plc (LON:POLB) CEO Jeremy Skillington joins DirectorsTalk Interviews to discuss partnering with leading global biopharma services company Eurofins Genomics. Jeremy tells us more about this exciting step in its AI data analysis programme, clarifies the ownership of the human challenge samples, the next step in the data analysis programme, how AI analysis will be used to discover new drugs and explains the benefits of analysing data using AI.

Poolbeg Pharma plc is a clinical stage infectious disease pharmaceutical company, with a novel capital light, clinical model which enables them to develop multiple products faster and more cost effectively than the traditional biotech model.

You might also enjoy reading Poolbeg Pharma Powering Ahead with Groundbreaking Treatments and Strategic Growth, Cavendish Comments

Find more news, interviews, share price & company profile here for:Poolbeg Pharma plc

Share this interview

Other Interviews

More News

Poolbeg Pharma delighted with progress made March 30, 2023
Poolbeg Pharma POLB 001 patent portfolio strengthened March 8, 2023
Poolbeg Pharma receive positive results from POLB 001 LPS Human Challenge Trial March 2, 2023
Poolbeg Pharma Investment Case February 20, 2023
UPDATED: Poolbeg Pharma strategic expansion of POLB 001 into oncology January 16, 2023
Poolbeg Pharma POLB 001 shows promising results in initial data analysis for Severe Influenza Treatment January 9, 2023
Poolbeg identifies new potential drug candidates for Respiratory Syncytial Virus infections December 21, 2022
Poolbeg exclusively licences innovative oral delivery technology December 14, 2022
Poolbeg Pharma POLB 001 LPS human challenge clinical trial successfully completed December 12, 2022
Poolbeg Pharma CytoReason analysis of human challenge trial data on track to deliver outputs in Q2 2023 November 29, 2022

Search

Useful links

Disclaimer

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

© 2024 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.